Results of open non-randomized non-comparative study of efficacy and safety of Levofloxacin in community-acquired pneumonia and exacerbation of chronic bronchitis
Abstract
The aim of the present study was to evaluate an efficacy and safety of 7-day outpatient therapy with Levofloxacin (500 mg once a day) in adults upward 18 years with community-acquired pneumonia or exacerbation of chronic bronchitis. The study involved 925 patients from 51 sites of Russian Federation: 442 patients with community-acquired pneumonia and 483 patients with exacerbation of chronic bronchitis. The clinical efficacy was assessed in 704 of them in 8-11 days after the finish of taking Levofloxacin. It was 97.5% in chronic bronchitis patients and 97.6% in pneumonia patients. The drug was well-tolerated. No-one patient was excluded from the study due to occurrence of serious adverse effects.
About the Authors
A. G. Chuchalin
Научно-исследовательский институт пульмонологии Минздрава РФ
Russian Federation
Russian Federation
A. I. Sinopalnikov
Государственный институт усовершенствования врачей Минобразования РФ
Russian Federation
Russian Federation
O. V. Fesenko
Государственный институт усовершенствования врачей Минобразования РФ
Russian Federation
Russian Federation
References
1. Антибактериальная терапия пневмоний у взрослых. Учеб.-метод. пособие для врачей. М.; 1999.
2. Дворецкий Л.И., Яковлев С.В. Ошибки антибактериальной терапии инфекций дыхательных путей в амбулаторной практике. Инфекции и антимикроб, тер. 2001; 2: 49-54.
3. Спграчунский Л.С. Рост устойчивости бактериальных возбудителей инфекций дыхательных путей и место новых фторхинолонов. Клин, микробиол. и антимикроб. Химиотер. 2001; 1 (прил.): 8-12.
4. Страчунский Л.С. Антибактераильная терапия внебольничной пневмонии в амбулаторных условиях. Consilium Medicum 2002; 4: 180-185.
5. Хронические обструктивные болезни легких. Федеральная программа. М.; 1999.
6. Яковлев С.В. Значение новых фторхинолонов при внебольничных инфекциях дыхательных путей. Инфекции и антимикроб. тер. 2001; 3: 116-121.
7. Arai S., Gohara У., Kuwano К. et al. Antimycoplasmal activities of new quinolones, tetracyclines, and macrolides against Mycoplasma pneumoniae. Antimicrob. Agents Chemother. 1992; 36: 1322-1324.
8. Ball P. Epidemiology and treatment of chronic bronchitis and its exacerbations. Chest 1995; 108(suppl.): 43S-52S.
9. Blondeau J.M. Expanded activity and utility of the new fluoroquinolones: a review. Clin. Ther. 1999; 21: 3-40.
10. Carbon C., Ariza H., Rabie W.J. et al. Comparative study of levofloxacin and amoxycillin/clavulanic acid in adults with mildto-moderate community-acquired pneumonia. Clin. Microbiol. Infect. 1999; 5: 724-732.
11. Cassell G., Waites K., Pate M. et al. Comparative susceptibility of Mycoplasma pneumoniae to erythromycin, ciprofloxacin, and lomefloxacin. Rev. Infect. Dis. 1989; 11 (suppl.): S992.
12. Cook P., H oneybourne D. Chlamydia pneumoniae. J. Antimicrob. Chemother. 1994; 34: 859-873.
13. Dalhoff A. In vitro activities of quinolones. Exp. Opin. Invest. Drugs 1999; 8: 123-137.
14. Davis R., Bryson Ii. Levofloxacin: a review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. Drugs 1994; 47: 677-700.
15. lo. DeAbate C.A., Russell Al., McElvaine P. et al. Safety and efficacy of oral levofloxacin versus cefuroxime axetil in acute bacterial exacerbation of chronic bronchitis. Respir. Care. 1997; 42: 206-213.
16. Fang G., Fine M., Orloff J. et al. New and emerging etiologies for community-acquired pneumonia with implications for therapy: a prospective multicenter study of 359 cases. Medicine (Baltimore) 1990; 69: 307-316.
17. File T.M. Jr., Segreti J., Dunbar L. et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob. Agents Chemother. 1997; 41: 1965-1972.
18. File T.M ., Tan J.S., Plouffe J.F. The role of atypical pathogens: Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella pneumophila in respiratory infection. Infect. Dis. Clin. North. Am. 1998; 12: 569-592
19. Goldstein F.W ., Acar J.F. Antimicrobial resistance among lower respiratory tract isolates of Streptococcus pneumoniae: results of a 1992-93 Western Europe and U SA collaborative surveillance study; the Alexander Project Collaborative Group. J. Antimicrob. Chemother. 1996; 38 (suppl.): 71-84.
20. Guthrie R. Community-acquired lower respiratory tract infections etiology and treatment. Chest 2001; 120 (6): 2021-2034.
21. Habib M.P., Gentry L.O., Rodriguez-Gomez G. et al. A multicenter, randomized study comparing the efficacy and safety of oral levofloxacin vs cefaclor in the treatment of acute bacterial exacerbations of chronic bronchitis. In: Program and abstracts of the 36th Interscience conference on antimicrobial agents and chemotherapy (IC A A C ). Washington, DC; 1996. 280, abstr. LM2.
22. Hammerschlag M., Hyman C., Roblin P. In vitro activities of five quinolones against Chlamydia pneumoniae. Antimicrob. Agents Chemother. 1992; 36: 682-683.
23. Hammerschlag M ., Chirgwin K., Roblin P. et al. Persistent infection with Chlamydia pneumoniae following acute respiratory illness. Clin. Infect. Dis. 1992; 14: 178-182
24. Hammerschlag M. Atypical pneumonia in children. Adv. Pediatr. Infect. Dis. 1995; 10: 1-39.
25. Johnson D., Cunha B. Atypical pneumonias: clinical and extrapulmonary features of Chlamydia, Mycoplasma, and Legionella infections. Postgrad. Med. 1993; 93: 69-82.
26. Macfarlane J., Colville A., Guion A. et al. Prospective study of etiology and outcome of adult lower-respiratory-tract infections in the community. Lancet 1993; 341: 511-514.
27. Mandell L. Community-acquired pneumonia: etiology, epidemiology, and treatment. Chest 1995; 108 (suppl.): 35S-42S.
28. Shah P.M., Maesen F.P.V., Dolmann A. et al. Levofloxacin versus cefuroxime axetil in the treatment of acute exacerbation of chronic bronchitis: results of a randomized, double- blind study. J. Antimicrob. Chemother. 1999; 43: 529-539.
29. Thornsberry C., Ogilvie P., Kahn J. et al. Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. Diagn. Microbiol. Infect. Dis. 1997; 29: 249-257.
30. Wiessenger B.A., Kabin J.B., Williams R.R. et al. J. Antimicrob. Chemother. 1999; 44 (suppl.A).
Review
For citations:
Chuchalin A.G., Sinopalnikov A.I., Fesenko O.V. Results of open non-randomized non-comparative study of efficacy and safety of Levofloxacin in community-acquired pneumonia and exacerbation of chronic bronchitis. PULMONOLOGIYA. 2002;(4):71-78. (In Russ.)
Views:
153
Email this article 